Cargando…
Interferon and interferon-induced cytokines as markers of impending clinical progression in ANA(+) individuals without a systemic autoimmune rheumatic disease diagnosis
BACKGROUND: Elevated levels of interferons (IFNs) are a characteristic feature of systemic autoimmune rheumatic diseases (SARDs) and may be useful in predicting impending symptomatic progression in anti-nuclear antibody-positive (ANA(+)) individuals lacking a SARD diagnosis. Typically, these are mea...
Autores principales: | , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9912609/ https://www.ncbi.nlm.nih.gov/pubmed/36765391 http://dx.doi.org/10.1186/s13075-023-02997-w |
_version_ | 1784885242248560640 |
---|---|
author | Kim, Sonya T. Muñoz-Grajales, Carolina Dunn, Shannon E. Schneider, Raphael Johnson, Sindhu R. Touma, Zahi Ahmad, Zareen Bonilla, Dennisse Atenafu, Eshetu G. Hiraki, Linda T. Bookman, Arthur Wither, Joan |
author_facet | Kim, Sonya T. Muñoz-Grajales, Carolina Dunn, Shannon E. Schneider, Raphael Johnson, Sindhu R. Touma, Zahi Ahmad, Zareen Bonilla, Dennisse Atenafu, Eshetu G. Hiraki, Linda T. Bookman, Arthur Wither, Joan |
author_sort | Kim, Sonya T. |
collection | PubMed |
description | BACKGROUND: Elevated levels of interferons (IFNs) are a characteristic feature of systemic autoimmune rheumatic diseases (SARDs) and may be useful in predicting impending symptomatic progression in anti-nuclear antibody-positive (ANA(+)) individuals lacking a SARD diagnosis. Typically, these are measured by their effect on gene expression in the blood, which has limited their utility in clinical settings. Here, we assessed whether the measurement of serum IFN-α or selected IFN-induced cytokines accurately mirrors IFN-induced gene expression in ANA(+) individuals and investigated their utility as biomarkers of clinical progression. METHODS: A total of 280 subjects were studied, including 50 ANA(−) healthy controls, 160 ANA(+) individuals without a SARD diagnosis (96 asymptomatic, 64 with undifferentiated connective tissue disease), and 70 SARD patients. IFN-induced gene expression was measured by nanoString and cytokine levels by ELISA or Simoa. ANA(+) individuals lacking a SARD diagnosis who had the new onset of SARD criteria over the subsequent 2 years were defined as progressors. RESULTS: Measurement of IFN-α levels by high-sensitivity ELISA or Simoa correlated much better with IFN-induced gene expression than measurement of CXCL-10 or Galectin-9 levels. Despite this, high CXCL-10 and Galectin-9 levels were better predictors of subsequent progression in ANA(+) individuals than measures of IFN-α or IFN-induced gene expression with the optimal combination of predictive cytokines (CXCL-10 and IFN-α as measured by ELISA), resulting in a specificity and positive predictive value of 100%. CONCLUSION: Easily performed ELISA assays for CXCL-10 and IFN-α can be used to predict ANA(+) individuals at high risk of imminent symptomatic progression. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1186/s13075-023-02997-w. |
format | Online Article Text |
id | pubmed-9912609 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2023 |
publisher | BioMed Central |
record_format | MEDLINE/PubMed |
spelling | pubmed-99126092023-02-11 Interferon and interferon-induced cytokines as markers of impending clinical progression in ANA(+) individuals without a systemic autoimmune rheumatic disease diagnosis Kim, Sonya T. Muñoz-Grajales, Carolina Dunn, Shannon E. Schneider, Raphael Johnson, Sindhu R. Touma, Zahi Ahmad, Zareen Bonilla, Dennisse Atenafu, Eshetu G. Hiraki, Linda T. Bookman, Arthur Wither, Joan Arthritis Res Ther Research BACKGROUND: Elevated levels of interferons (IFNs) are a characteristic feature of systemic autoimmune rheumatic diseases (SARDs) and may be useful in predicting impending symptomatic progression in anti-nuclear antibody-positive (ANA(+)) individuals lacking a SARD diagnosis. Typically, these are measured by their effect on gene expression in the blood, which has limited their utility in clinical settings. Here, we assessed whether the measurement of serum IFN-α or selected IFN-induced cytokines accurately mirrors IFN-induced gene expression in ANA(+) individuals and investigated their utility as biomarkers of clinical progression. METHODS: A total of 280 subjects were studied, including 50 ANA(−) healthy controls, 160 ANA(+) individuals without a SARD diagnosis (96 asymptomatic, 64 with undifferentiated connective tissue disease), and 70 SARD patients. IFN-induced gene expression was measured by nanoString and cytokine levels by ELISA or Simoa. ANA(+) individuals lacking a SARD diagnosis who had the new onset of SARD criteria over the subsequent 2 years were defined as progressors. RESULTS: Measurement of IFN-α levels by high-sensitivity ELISA or Simoa correlated much better with IFN-induced gene expression than measurement of CXCL-10 or Galectin-9 levels. Despite this, high CXCL-10 and Galectin-9 levels were better predictors of subsequent progression in ANA(+) individuals than measures of IFN-α or IFN-induced gene expression with the optimal combination of predictive cytokines (CXCL-10 and IFN-α as measured by ELISA), resulting in a specificity and positive predictive value of 100%. CONCLUSION: Easily performed ELISA assays for CXCL-10 and IFN-α can be used to predict ANA(+) individuals at high risk of imminent symptomatic progression. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1186/s13075-023-02997-w. BioMed Central 2023-02-10 2023 /pmc/articles/PMC9912609/ /pubmed/36765391 http://dx.doi.org/10.1186/s13075-023-02997-w Text en © The Author(s) 2023 https://creativecommons.org/licenses/by/4.0/Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) . The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/ (https://creativecommons.org/publicdomain/zero/1.0/) ) applies to the data made available in this article, unless otherwise stated in a credit line to the data. |
spellingShingle | Research Kim, Sonya T. Muñoz-Grajales, Carolina Dunn, Shannon E. Schneider, Raphael Johnson, Sindhu R. Touma, Zahi Ahmad, Zareen Bonilla, Dennisse Atenafu, Eshetu G. Hiraki, Linda T. Bookman, Arthur Wither, Joan Interferon and interferon-induced cytokines as markers of impending clinical progression in ANA(+) individuals without a systemic autoimmune rheumatic disease diagnosis |
title | Interferon and interferon-induced cytokines as markers of impending clinical progression in ANA(+) individuals without a systemic autoimmune rheumatic disease diagnosis |
title_full | Interferon and interferon-induced cytokines as markers of impending clinical progression in ANA(+) individuals without a systemic autoimmune rheumatic disease diagnosis |
title_fullStr | Interferon and interferon-induced cytokines as markers of impending clinical progression in ANA(+) individuals without a systemic autoimmune rheumatic disease diagnosis |
title_full_unstemmed | Interferon and interferon-induced cytokines as markers of impending clinical progression in ANA(+) individuals without a systemic autoimmune rheumatic disease diagnosis |
title_short | Interferon and interferon-induced cytokines as markers of impending clinical progression in ANA(+) individuals without a systemic autoimmune rheumatic disease diagnosis |
title_sort | interferon and interferon-induced cytokines as markers of impending clinical progression in ana(+) individuals without a systemic autoimmune rheumatic disease diagnosis |
topic | Research |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9912609/ https://www.ncbi.nlm.nih.gov/pubmed/36765391 http://dx.doi.org/10.1186/s13075-023-02997-w |
work_keys_str_mv | AT kimsonyat interferonandinterferoninducedcytokinesasmarkersofimpendingclinicalprogressioninanaindividualswithoutasystemicautoimmunerheumaticdiseasediagnosis AT munozgrajalescarolina interferonandinterferoninducedcytokinesasmarkersofimpendingclinicalprogressioninanaindividualswithoutasystemicautoimmunerheumaticdiseasediagnosis AT dunnshannone interferonandinterferoninducedcytokinesasmarkersofimpendingclinicalprogressioninanaindividualswithoutasystemicautoimmunerheumaticdiseasediagnosis AT schneiderraphael interferonandinterferoninducedcytokinesasmarkersofimpendingclinicalprogressioninanaindividualswithoutasystemicautoimmunerheumaticdiseasediagnosis AT johnsonsindhur interferonandinterferoninducedcytokinesasmarkersofimpendingclinicalprogressioninanaindividualswithoutasystemicautoimmunerheumaticdiseasediagnosis AT toumazahi interferonandinterferoninducedcytokinesasmarkersofimpendingclinicalprogressioninanaindividualswithoutasystemicautoimmunerheumaticdiseasediagnosis AT ahmadzareen interferonandinterferoninducedcytokinesasmarkersofimpendingclinicalprogressioninanaindividualswithoutasystemicautoimmunerheumaticdiseasediagnosis AT bonilladennisse interferonandinterferoninducedcytokinesasmarkersofimpendingclinicalprogressioninanaindividualswithoutasystemicautoimmunerheumaticdiseasediagnosis AT atenafueshetug interferonandinterferoninducedcytokinesasmarkersofimpendingclinicalprogressioninanaindividualswithoutasystemicautoimmunerheumaticdiseasediagnosis AT hirakilindat interferonandinterferoninducedcytokinesasmarkersofimpendingclinicalprogressioninanaindividualswithoutasystemicautoimmunerheumaticdiseasediagnosis AT bookmanarthur interferonandinterferoninducedcytokinesasmarkersofimpendingclinicalprogressioninanaindividualswithoutasystemicautoimmunerheumaticdiseasediagnosis AT witherjoan interferonandinterferoninducedcytokinesasmarkersofimpendingclinicalprogressioninanaindividualswithoutasystemicautoimmunerheumaticdiseasediagnosis |